The organization cites limitations to a study published in the American Journal of Clinical Nutrition, which found no benefit of maternal DHA supplementation on infant visual acuity.
Past clinical research suggests that women supplementing with omega-3 docosahexaenoic acid (DHA) during pregnancy may improve visual acuity in infants, but research published online on April 13 in the American Journal of Clinical Nutrition suggests no such benefit.
Australian researchers assigned 182 women in singleton pregnancies to consume DHA-rich fish capsules (800 mg of DHA and 100 mg of EPA) or vegetable capsules (control) daily from mid-pregnancy to delivery. Visual evoked potential (VEP) acuity and latency was then measured in each infant at four months of age.
The researchers concluded that there were no significant differences in VEP acuity or latency in infants of either group.
The Global Organization for EPA and DHA Omega-3 (GOED; Salt Lake City) has since responded to the study, with a review in its newsletter, Advances in EPA and DHA Research.
GOED’s review notes several potential limitations of the study. The period of supplementation-beginning at mid-pregnancy-may have been too short to produce a significant effect. Blood levels of EPA and DHA and dietary intake of EPA and DHA were not recorded, so subjects in the groups may have had significantly different omega-3 levels beyond what was given through supplements.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.